MAGEA3 and acute myeloid leukemia: In this report, we have extended our prior findings by demonstrating that AML patients at two separate institutions receiving standard doses and schedules of decitabine exhibit increased mRNA and protein levels of the CTA genes NY-ESO-1 and MAGEA3/A6 in circulating blasts.